NCT02891590View on ClinicalTrials.gov

Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Chronic Lymphocytic LeukemiaB-cell Lymphomas
Interventions
DRUG

DTRMWXHS-12

Trial Locations (1)

Unknown

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Zhejiang DTRM Biopharma

INDUSTRY

NCT02891590 - Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas | Biotech Hunter | Biotech Hunter